NCT05354414View on ClinicalTrials.gov

Virtual Reality for the Mitigation of Anxiety During Intrathecal Administration in Participants With Spinal Muscular Atrophy

NACompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

May 11, 2022

Primary Completion Date

July 12, 2024

Study Completion Date

July 12, 2024

Conditions
Spinal Muscular Atrophy (SMA)
Interventions
DEVICE

Virtual reality

Administered as specified in the treatment arm.

PROCEDURE

Standard of Care

Administered as specified in the treatment arm.

Trial Locations (12)

29609

CHRU de Brest, Brest

31059

CHU de Toulouse, Toulouse

34295

CHU Montpellier, Montpellier

49933

Chu d' Angers, Angers

54511

CHU de Nancy, Nancy

59000

Chu de Lille, Lille

63003

Chu de Clermont Ferrand, Clermont-Ferrand

67200

Hôpitaux Universitaires de Strasbourg, Strasbourg

75015

APHP- Necker Paris, Paris

75571

APHP- Trousseau Paris, Paris

92380

APHP- Raymond Poincaré Paris, Garches

06000

Chu de Nice, Nice

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT05354414 - Virtual Reality for the Mitigation of Anxiety During Intrathecal Administration in Participants With Spinal Muscular Atrophy | Biotech Hunter | Biotech Hunter